Annandale, VA; August 5, 2020
CARE-ID has made very good progress toward its total enrollment goal with 20% achieved to date. With these initial participants already signed up and receiving their first infusions, CARE-ID is off to a good start for this landmark clinical research study. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful results in the laboratory setting. As of August 3rd, over 200 participants have enrolled in the study nation-wide and have received the one-time, one-hour infusion in the outpatient setting. To continue making its progress, CARE-ID is looking for additional adults in the Northern Virginia area ages 18 or older to participate in the study who have recently tested positive for COVID-19 and are not hospitalized.